Key result
Direct factor Xa inhibitors (Apixaban, Edoxaban, and Rivaroxaban) were associated with acute renal failure and renovascular disorders, with Edoxaban showing the strongest correlation.
Why the study?
Factor Xa inhibitors may induce nephrotoxicity despite FDA approval for thrombotic diseases, raising concerns due to potentially severe consequences.
Do direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) increase the risk of nephrotoxic adverse events compared to other drugs in the FAERS database?
Observational
Do direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) increase the risk of nephrotoxic adverse events compared to other drugs in the FAERS database?
Answers are grounded in this paper and cite their sources.
Direct factor Xa inhibitors, particularly edoxaban, are associated with an increased risk of nephrotoxic adverse events in real-world pharmacovigilance data, highlighting the need for renal function monitoring.
BACKGROUND: Factor Xa inhibitors (FXaIs) may induce nephrotoxicity despite their FDA approval for thrombotic diseases, which has raised concerns due to its severe consequences. This study utilizes the FAERS database to assess the potential link between direct FXaIs and nephrotoxicity. METHODS: Data from the FAERS database, spanning from the third quarter of 2011 to the fourth quarter of 2023, were used to perform a disproportionality analysis on Apixaban, Edoxaban, and Rivaroxaban. Disproportionality analysis and statistical processing were conducted using R software. RESULTS: Descriptive analysis revealed that males and individuals aged 65-85 are more susceptible to nephrotoxic adverse events. The disproportionality analysis indicated that all three drugs are associated with acute renal failure and renovascular disorders, with Edoxaban showing the strongest correlation. CONCLUSIONS: This study quantitatively analysed the relative risk of nephrotoxic adverse reactions associated with direct FXaIs, emphasizing the importance of renal function monitoring for these medications. The results indicate that Edoxaban has a significant association with nephrotoxicity, necessitating closer attention to its use and recommending additional renal function tests and drug concentration testing for high-risk patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) conducted an observational in Thrombotic diseases. Direct factor Xa inhibitors (Apixaban, Edoxaban, Rivaroxaban) was evaluated on Nephrotoxic adverse events (acute renal failure and renovascular disorders). Direct factor Xa inhibitors (Apixaban, Edoxaban, and Rivaroxaban) were associated with acute renal failure and renovascular disorders, with Edoxaban showing the strongest correlation.
Synapse has enriched 10 related papers. Consider them for comparative context: